Core Viewpoint - The study highlights that intravesical administration of Bacillus Calmette-Guérin (BCG) vaccine can reprogram hematopoietic stem/progenitor cells (HSPC) to enhance anti-tumor immunity, indicating its potential in cancer immunotherapy [1][2][4][6]. Group 1: Mechanism of Action - BCG vaccine can colonize the bone marrow and reprogram HSPC, enhancing myeloid hematopoiesis in both mice and humans [3][4]. - The reprogrammed HSPC can generate neutrophils, monocytes, and dendritic cells, which reshape the tumor microenvironment and drive T cell-dependent anti-tumor responses [3][4]. Group 2: Key Findings - The study confirms that intravesical BCG administration leads to systemic reprogramming of HSPC [4]. - The reprogramming of HSPC is dependent on INFγ and enhances the antigen-presenting function of myeloid cells [4]. - Reprogrammed myeloid cells increase T cell infiltration and work synergistically with PD-1 blockade for anti-cancer effects [4][6]. Group 3: Implications - The findings underscore the broad potential of HSPC reprogramming in enhancing T cell-dependent tumor immunity, suggesting a novel approach in cancer treatment [6].

Core Viewpoint - The article highlights the significant contributions of Professor Danyang in the field of sleep research and her recent affiliation with Shenzhen Medical Academy, where she will establish a Sleep and Consciousness Laboratory [1][4]. Group 1: Professor Danyang's Background - Professor Danyang graduated from Peking University with a degree in Physics and later pursued a PhD in Biology at Columbia University, followed by postdoctoral research at Rockefeller University and Harvard Medical School [4]. - She has been a faculty member at the University of California, Berkeley since 1997, focusing on the neural circuits that control sleep and the functions of the prefrontal cortex [4][21]. Group 2: Recent Research Contributions - On December 8, 2023, Professor Danyang's team published a study in Cell, revealing that frontal cortical ignition, related to consciousness awareness, is strongly suppressed during NREM sleep in mice due to cholinergic modulation [7][10]. - On January 18, 2024, a study published in Nature Neuroscience demonstrated that microglia can promote sleep through calcium-dependent modulation of norepinephrine transmission, suggesting a protective role for microglia in brain health [12][13]. - On January 17, 2025, a study in Science Advances explored how activation of locus coeruleus noradrenergic neurons rapidly increases homeostatic sleep pressure, indicating a mechanism for sleep regulation [15][17]. Group 3: Implications for Sleep Research - The findings from Professor Danyang's research suggest that understanding the mechanisms of sleep regulation could have implications for addressing sleep disruptions associated with neurodegenerative diseases like Alzheimer's [13]. - The research emphasizes the importance of microglial function in maintaining sleep and brain homeostasis, potentially offering insights into therapeutic strategies for sleep-related disorders [13]. - The studies collectively indicate that the functional fatigue of locus coeruleus neurons may lead to increased sleep pressure, providing a new perspective on the relationship between wakefulness and sleep [17].

Core Viewpoint - The development and application of GLP-1 receptor agonists, particularly Semaglutide, have significantly transformed obesity treatment, demonstrating effective weight loss and potential heart protection properties [2][5]. Group 1: Mechanism of Action - Semaglutide primarily reduces weight by suppressing appetite, leading to decreased caloric intake, although its direct effects on peripheral metabolism remain unclear [2]. - Recent research indicates that Semaglutide's effects on energy balance are mediated by Adcyap1+ neurons in the dorsal vagal complex (DVC), which play a crucial role in appetite regulation and metabolism [3][5]. - Activation of Adcyap1+ neurons promotes fat loss without significant muscle loss and minimizes side effects like nausea, paving the way for safer and more effective weight loss medications [6][8]. Group 2: Research Findings - The study published in Cell Metabolism reveals that Semaglutide activates specific neurons in the DVC, leading to reduced food intake and weight loss while enhancing fat utilization [3][5]. - The research team found that eliminating Adcyap1+ neurons in the AP/NTS significantly reversed Semaglutide's appetite-suppressing effects and fat reduction, indicating their critical role in the drug's mechanism [6][8]. - The findings provide a theoretical foundation for developing more precise anti-obesity therapies that target the Adcyap1+ neuronal pathway, emphasizing a "fat loss while preserving muscle" approach [8].

Core Viewpoint - The research highlights a significant breakthrough in the use of allogeneic CAR-T cell therapy for treating autoimmune diseases, specifically refractory systemic lupus erythematosus (SLE), demonstrating long-term remission and safety [2][3][4]. Group 1: Research Findings - The study published in Cell reported the successful use of allogeneic CD19-targeted CAR-T cells (TyU19) in treating refractory immune-mediated necrotizing myopathy and diffuse cutaneous systemic sclerosis, achieving long-term remission [1]. - In a subsequent study published in Med, the same CAR-T cell therapy was shown to effectively treat three patients with refractory SLE, leading to significant reductions in serum autoantibodies and achieving clinical remission as defined by the SRI-4 standard [3][6][7]. - The therapy demonstrated good tolerance, with no occurrences of graft-versus-host disease (GvHD), cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) reported during the study [9][10]. Group 2: Methodology and Safety - The clinical trial involved three patients with severe refractory SLE, where CAR-T cells were infused at a dose of 1 million cells per kilogram, and safety was assessed through the monitoring of potential adverse events [5][6]. - The CAR-T cells showed robust in vivo proliferation, peaking on day 14 post-infusion, and effectively eliminated B cells from the patients, leading to a significant decrease in B cell counts [6][9]. - The study utilized a low-intensity lymphocyte-depleting regimen, and even without pre-treatment lymphocyte clearance, TyU19 exhibited remarkable therapeutic efficacy, indicating a new potential pathway for treating autoimmune diseases [11].

H3K9me3 的表观遗传维持依赖于 HP1 蛋白识别预先存在的甲基化标记，进而招募甲基转移酶 SUV39H1 对邻近新掺入的组蛋白进行甲基化修饰，形成自我强化的"读-写"正反馈环路。然而，这种正反馈如何被限 制以实现 H3K9me3 的动态稳态，其分子机制尚不明确。 2 02 5 年 5 月 29 日，中山大学肿瘤防治中心 康铁邦 / 武远众 团队 （ 周立文 、 陈振轩 、 邹叶子 为共 同第一作者） 在国际顶尖学术期刊 Science 上 发表了题为： ASB7 is a negative regulator of H3K9me3 homeostasis 的研究 论文 。 该研究表明， E3 泛素连接酶 CUL5 ASB7 发挥着在 H3K9me3 的动态稳态中发挥着 刹车器 的作用， 通过 细胞周期依赖性降解 SUV39H1 来 保障 H3K9me3 在细胞周期中精准重建， 进而 维持异染色质在细胞增 殖过程中的结构稳定 。 编辑丨王多鱼 排版丨水成文 H3K9me3 （组蛋白H3第9位赖氨酸三甲基化） 是表观遗传学中一种重要的染色质修饰标记，主要通过调 控染色质结构和基因表达参与多种生物学过程。 S ...

Core Viewpoint - Colorectal cancer (CRC) is a significant global health issue, being the third most common cancer and the second leading cause of cancer-related deaths, with nearly 2 million new cases and around 1 million deaths annually. The rising incidence among individuals under 50 years old highlights the urgency for effective treatment strategies [2][5]. Group 1: Research Findings - The study published in Cell Reports Medicine indicates that combining DR5-targeting antibody-drug conjugates (ADCs) with CDK inhibitors presents a promising treatment strategy for advanced colorectal cancer [3][10]. - DR5 expression is elevated in both microsatellite stable (MSS) and microsatellite instability-high (MSI-H) colorectal cancer, suggesting its potential as a clinical treatment target [5][7]. - The ADC Oba01, which targets DR5 and carries the microtubule inhibitor MMAE, has shown remarkable efficacy in various colorectal cancer models, regardless of their microsatellite status [5][6]. Group 2: Mechanism of Action - Functional multi-omics analysis revealed that the cell cycle pathway and CDK are critical synergistic targets for the antitumor activity of Oba01. The study demonstrated that Oba01 can work synergistically with the FDA-approved CDK inhibitor abemaciclib in relevant in vivo models [6][8]. - CDK inhibitors enhance the cytotoxic effects of Oba01 on tumor cells both in vitro and in vivo, reinforcing the potential of this combination therapy [8][10]. Group 3: Study Highlights - The research generated colorectal cancer PDX/PDX-like organoid models that retain the molecular characteristics of the original tumors [7]. - The study identified CDK as a synergistic target for Oba01 through RNA sequencing and proteomics [7][10]. - The combined targeting of DR5, microtubule assembly, and CDK may provide an effective treatment approach for MSS and MSI-H colorectal cancer patients expressing DR5 [10].

Core Viewpoint - The article discusses the phenomenon of "pivot penalty" in research, where scientists experience a decline in citation impact when they shift their research focus away from their original field, with the penalty increasing as the shift becomes more significant [2][5][9]. Group 1: Research Findings - A new framework was developed to quantify the extent of deviation from existing research fields, analyzing 25.8 million scientific papers and 1.7 million patents from 1970 to 2015 [4]. - The study found that the "pivot penalty" is prevalent across all scientific and patent fields, and its severity has intensified over the past 50 years [5]. - The greater the deviation from the original research area, the weaker the integration with existing knowledge systems, leading to lower publication success rates and citation counts [5][7]. Group 2: Impact of External Events - Unexpected shocks in research fields, such as the COVID-19 pandemic, can push researchers to new areas, but this often results in significant pivot penalties [7][9]. - During the pandemic, many researchers shifted to COVID-related studies, which had high impact due to increased demand for information, yet those who deviated further from their original fields saw a notable decline in their research impact [7][9]. Group 3: Strategies to Mitigate Pivot Penalty - Strategies to reduce the pivot penalty include publishing new research in journals where the researcher has previously published, allowing familiar readership to engage with the new work [7]. - The findings highlight the need for researchers to adapt to new opportunities and challenges, which has significant implications for individual researchers, research institutions, and scientific policy [7][9]. Group 4: Editorial Perspective - The editorial in Nature emphasizes that researchers should not be penalized for shifting fields, as the COVID-19 pandemic demonstrated the value of adapting research directions [8][10]. - It argues for a broader understanding of research value beyond citation counts, advocating for evaluation metrics that reflect the benefits of interdisciplinary collaboration [10].

Core Viewpoint - The article discusses the development of a large-scale Pan-Cancer Proteome Atlas (TPCPA) that aims to enhance the understanding of cancer biology and identify therapeutic targets and biomarkers through mass spectrometry-based analysis of protein expression across various cancer types [2][4]. Group 1: Research Overview - The TPCPA covers 22 cancer types, including 18 solid tumors and 4 non-solid tumors, analyzing 999 primary tumor samples and quantifying 9,670 proteins [5][6]. - The study identifies multiple pan-cancer and specific protein biomarkers, potential therapeutic targets, and classifiers for cancer subtypes [2][6]. Group 2: Methodology and Findings - The research utilizes data-independent acquisition mass spectrometry (DIA-MS) to construct the proteome atlas, facilitating a comprehensive analysis of protein expression characteristics both inter- and intra-cancer types [4][6]. - The study highlights specific E3 ubiquitin ligases, such as HERC5 and RNF5, that are highly expressed in esophageal and liver cancers, respectively, as potential targets for protein-targeted degradation therapies [6]. Group 3: Cancer Subtype Classification - An analysis of 195 colorectal cancer cases led to the identification of consensus molecular subtypes (CMS) and two immune subtypes with prognostic value [7]. - A cancer subtype classifier based on 75 proteins was developed, demonstrating excellent performance (AUC greater than 0.98) in internal validation and four independent cohorts, including metastatic cancers [7]. Group 4: Data Accessibility - The research team has made all TPCPA data publicly available for free access and use through a dedicated portal [9].

Core Viewpoint - The article highlights significant research contributions from Chinese scholars published in the prestigious journal Cell, focusing on advancements in AI-driven protein activation, nuclear stress bodies' role in inflammation regulation, and a novel bile acid's impact on glucose homeostasis [2][4][15]. Group 1: AI-Driven Protein Activation - A research team from Peking University developed a machine-learning-assisted platform called CAGE-Prox vivo for precise protein activation in living mice, enabling real-time biological studies and therapeutic interventions [4][7]. - The platform allows for the temporary blocking of target protein functions and can be triggered by small molecules, facilitating specific control over protein-protein interactions [7]. Group 2: Nuclear Stress Bodies and Inflammation - A study by the Chinese Academy of Sciences explored the assembly and function of nuclear stress bodies (nSB) under stress conditions, revealing their role in enhancing the transcription of NFIL3, which suppresses inflammatory responses [8][9]. - The research indicates that the expression of NFIL3 is positively correlated with the survival rates of sepsis patients, suggesting a potential therapeutic target for precise diagnosis and treatment of sepsis [12][13]. Group 3: Microbial Bile Acids and Glucose Homeostasis - A collaborative study identified a novel bile acid receptor, MRGPRE, activated by a microbial amino-acid-conjugated bile acid, tryptophan-cholic acid (Trp-CA), which improves glucose regulation [15][18]. - The findings reveal a new mechanism for GLP-1 secretion regulation via MRGPRE, providing insights for developing new diabetes medications without the side effects associated with traditional bile acids [18].

Core Viewpoint - The study demonstrates the safety and potential of BCMA-targeted CAR-T cell therapy in treating refractory chronic inflammatory demyelinating polyneuropathy (CIDP) and provides insights into the molecular mechanisms of disease remission [3][10]. Group 1: CAR-T Cell Therapy Overview - Since 2017, the FDA has approved seven CAR-T cell therapies for treating blood cancers, showing strong therapeutic effects [2]. - CAR-T cell therapy has also shown promising results in treating various autoimmune diseases, including systemic lupus erythematosus and myasthenia gravis [2]. Group 2: CIDP and Treatment Challenges - CIDP is a chronic autoimmune disease affecting the peripheral nervous system, with first-line treatments including intravenous immunoglobulin and steroids [2]. - Approximately 15% of CIDP patients do not respond to current treatment methods [2]. Group 3: Research Findings - The study published in Cell by researchers from Huazhong University of Science and Technology confirmed the safety and potential of BCMA-targeted CAR-T cell therapy in CIDP [3][5]. - The therapy was administered to two patients, both showing manageable safety profiles; one patient experienced disease relapse after 12 months, while the other maintained clinical remission for over 24 months [5][10]. - Multi-omics analysis was conducted on patient samples to understand the molecular mechanisms behind the therapy's efficacy and the differing patient responses [5]. Group 4: Mechanisms of Disease Relapse - Disease relapse in one patient was associated with the reactivation of pathogenic B cells and the reappearance of autoantibodies [6][7]. - Metabolic reprogramming of B cells characterized by excessive glycolysis was linked to disease relapse, which can be regulated by factor RFX5 [6][7].